| Axonics Inc (AXNX) | |||
|---|---|---|---|
| 66.54 -0.1 (-0.15%) | 04-25 16:00 | ||
| Open: | 66.5 | Pre. Close: | 66.64 |
| High: | 66.75 | Low: | 66.47 |
| Volume: | 465,964 | Market Cap: | 3,394(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 79.92 One year: 81.37 |
| Support: | Support1: 66.42 Support2: 55.26 |
| Resistance: | Resistance1: 68.43 Resistance2: 69.67 |
| Pivot: | 67.25  |
| Moving Averages: | MA(5): 66.69 MA(20): 67.66 MA(100): 65.85  MA(250): 58.94 |
| MACD: | MACD(12,26): -0.40 Signal(12,26,9): -0.26 |
| %K %D: | %K(14,3): 6.92 %D(3): 5.07 |
| RSI: | RSI(14): 33.02 |
| 52-Week: | High: 69.68 Low: 47.59 Change(%): 17.4 |
| Average Vol(K): | 3-Month: 891 10-Days: 725 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 66.939 - 67.31 | 67.31 - 67.611 |
| Low: | 65.298 - 65.835 | 65.835 - 66.271 |
| Close: | 65.755 - 66.547 | 66.547 - 67.19 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ AXNX ] has closed above bottom band by 11.6%. Bollinger Bands are 59.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Medical - Devices | |
| Shares Out. (M) | 51.00 |
| Shares Float (M) | 50.43 |
| % Held by Insiders | 1.07 |
| % Held by Institutions | 100.71 |
| Shares Short (K) | 3440 |
| Shares Short Prior Month (K) | 2820 |
| Stock Financials | |
|---|---|
| EPS | -0.120 |
| Book Value (p.s.) | 12.560 |
| Profit Margin | -1.66 |
| Operating Margin | 3.93 |
| Return on Assets (ttm) | -0.4 |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | 27.7 |
| Gross Profit (p.s.) | |
| Sales Per Share | 7.184 |
| EBITDA (p.s.) | 0.153 |
| Qtrly Earnings Growth | 844.80 |
| Operating Cash Flow (M) | -2.02 |
| Levered Free Cash Flow (M) | -6.82 |
| Stock Valuation | |
|---|---|
| PE Ratio | -554.50 |
| PEG Ratio | 2.26 |
| Price to Book value | 5.30 |
| Price to Sales | 9.26 |
| Price to Cash Flow | -1679.97 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
